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Proteinuria (albuminuria) reflects dysfunction of the
glomerular permeability barrier in which inflammatory
cytokines play a key role. Pentoxifylline (PTX) is a
phosphodiesterase inhibitor that possesses potent
anti-inflammatory and immunomudulatory effects. This study
evaluated the effectiveness of PTX to reduce proteinuria and
inflammatory mediators in patients with proteinuric primary
glomerular diseases. Seventeen patients with primary
glomerular diseases, a persistent spot proteinuria exceeding
1.5 g/g creatinine (Cr) and a glomerular filtration rate
between 24 and 115 ml/min/1.73 m2 were treated with PTX
400 mg twice daily for 6 months. Before and after the
treatment, serum Cr, plasma renin activity and aldosterone
concentrations, plasma and urinary tumor necrosis factor
(TNF)-a, interleukin-1b and monocyte chemoattractant
protein (MCP)-1, as well as urinary protein and Cr were
measured. PTX significantly reduced urinary protein
excretion, along with an increase of serum albumin. A
significant correlation existed between the basal urinary
protein/Cr and the basal urinary MCP-1/Cr ratios. PTX
lowered the urinary MCP-1/Cr ratio, and the percent
reduction of urinary protein/Cr ratio correlated directly with
the precent decrease of urinary MCP-1/Cr ratio after PTX
treatment. There was no significant change in blood
pressure, renal function, biochemical parameters, plasma
renin activity and aldosterone concentrations, or plasma
TNF-a and MCP-1 levels during the study. In conclusion,
administration of PTX 800 mg per day is safe and effective for
reducing proteinuria in patients with proteinuric primary
glomerular diseases. This beneficial effect occurs in close
association with a reduction of urinary MCP-1 excretion.
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Proteinuria (albuminuria) denotes a sign of glomerular
diseases and represents a marker of injury to the glomerular
permeability barrier.1,2 The pathogenesis of glomerular
proteinuria is not completely clear, but accumulating
evidence suggests that proinflammatory cytokines and
chemokines play a pivotal role. Patients with immunoglo-
bulin A (IgA) nephropathy and membranous glomerulo-
nephritis were reported to excrete excessive amount of
urinary tumor necrosis factor (TNF)-a and/or interleukin
(IL)-1b,3–6 and patients with diabetic nephropathy, lupus
nephritis, IgA nephropathy and active renal vasculitis were
found to have elevated urinary levels of monocyte chemoat-
tractant protein (MCP)-1.7–13 Regardless of the types of renal
diseases, these urinary inflammatory mediators correlate well
with the magnitude of proteinuria. The filtered and
subsequently reabsorbed proteins can in turn activate renal
tubular cells to release additional inflammatory mediators,
including TNF-a, IL-1b and MCP-1 into the interstitium,
contributing to progressive interstitial damage seen in many
proteinuric glomerular diseases.14,15 Thus, proteinuria is
generally regarded as the most powerful predictor for the
progression of glomerular diseases, and has been used as a
surrogate end point for therapeutic interventions.16,17
Indeed, there is evidence that an early reduction in
proteinuria following therapeutic interventions predicts an
improvement in renal outcomes.18 Given the importance of
TNF-a, IL-1b and MCP-1 in the pathogenesis of poteinuria,
it is conceivable that pharmacological agents capable of
suppressing these inflammatory mediators might have
therapeutic potential for proteinuric glomerular diseases.
Pentoxifylline (PTX) is a phosphodiesterase inhibitor that
is used clinically to treat patients with peripheral vascular
disorders.19 In addition to its hemorheologic activity, PTX
possesses potent anti-inflammatory and immunomodulatory
properties.20 In vivo, PTX has shown its ability to attenuate
o r i g i n a l a r t i c l e http://www.kidney-international.org
& 2006 International Society of Nephrology
Received 23 September 2005; revised 25 November 2005; accepted 8
January 2006; published online 15 March 2006
Correspondence: T-J Tsai, Renal Division, Department of Medicine, National
Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 100,
Taiwan. E-mail: paul@ha.mc.ntu.edu.tw
1410 Kidney International (2006) 69, 1410–1415
nephrotic syndrome secondary to membranous glomerulo-
nephritis21 and lupus nephritis,22 and to reduce subnephrotic
proteinuria of early and advanced diabetic nephropathy.23,24
However, data with respect to its effect on non-nephrotic
primary glomerular diseases are lacking. Moreover, the
antiproteinuric effect of PTX has been traditionally attributed
to downregulation of TNF-a.21,23 Whether or not other
inflammatory mediators are also affected by PTX has never
been studied. Our previous works have shown that PTX can
inhibit cytokine or albumin-induced MCP-1 production
in vitro,25 and attenuate proteinuria in association with
suppression of renal MCP-1 mRNA expression in experi-
mental glomerulonephritis.26,27 Thus, we hypothesize that
PTX might be effective in lowering proteinuria by modulat-
ing renal MCP-1 production in human glomerular diseases.
This study was thereby performed to investigate the potential
antiproteinuric and anti-inflammatory effects of PTX in
patients with proteinuric primary glomerular diseases.
RESULTS
Treatment with PTX for 6 months resulted in a significant
reduction of urinary protein/creatinine (Cr) ratio (before vs 6
months after PTX treatment, 2.8270.28 vs 1.7970.22 g/g Cr,
P¼ 0.006, Figure 1) and 24-h urinary protein excretion
(before vs 6 months after PTX treatment, 2.9570.31 vs
1.9570.25 g/g Cr/day, P¼ 0.001, Figure 1), along with an
increase of serum albumin (before vs 6 months after PTX
treatment, 3.670.1 vs 4.070.1 g/dl, P¼ 0.001, Table 1). PTX
significantly lowered urinary MCP-1/Cr (before vs 6 months
after PTX treatment, 789.97221.0 vs 423.0778.6 ng/g Cr,
P¼ 0.009), but not TNF-a/Cr or IL-1b/Cr ratio (Table 1 and
Figure 2). Plasma levels of TNF-a and MCP-1 did not change
appreciably before and after PTX treatment (Table 1).
Detectable levels of IL-1b were found in only three out of
34 plasma samples, and these were too few in number to
statistically analyze.
Correlation analysis showed a significant relationship
between the basal urinary protein/Cr ratio and the basal
urinary MCP-1/Cr (Spearman’s coefficient r¼ 0.650,
P¼ 0.009), but not TNF-a/Cr (Spearman’s coefficient
r¼ 0.020, P¼ 0.937), IL-1b/Cr (Spearman’s coefficient
r¼ 0.172, P¼ 0.492), plasma renin activity (Spearman’s
coefficient r¼ 0.115, P¼ 0.645), plasma aldosterone concen-
trations (Spearman’s coefficient r¼0.095, P¼ 0.702),
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Figure 1 | Single-voided (left panel) and 24-h (right panel) urinary
protein/Cr ratios in the studied patients before and after PTX
therapy.
Table 1 | Blood pressure, proteinuria, biochemistry, plasma
renin activity, plasma aldosterone, plasma and urinary
inflammatory mediators in the studied patients, before and 6
months after PTX therapy
Baseline Therapy P
Systolic BP (mm Hg) 13475 13074 0.359
Diastolic BP (mm Hg) 7872 7673 0.132
Spot proteinuria (g/g Cr) 2.8270.28 1.7970.22 0.006
24-h proteinuria (g/g Cr/day) 2.9570.31 1.9570.25 0.001
Glomerular filtrateion rate
(ml/min/1.73 m2)
64.976.7 68.478.2 0.917
Cr clearance (ml/min) 63.176.1 65.777.6 0.776
Cr (mg/dl) 1.270.1 1.270.2 0.854
Albumin (g/dl) 3.670.1 4.070.1 0.001
Cholesterol (mg/dl) 20778 20578 0.344
Alanine aminotransferase (U/l) 1973 1972 0.533
Hemoglobin (g/dl) 12.970.4 12.770.3 0.264
White blood cell (/ml) 7,4337359 7,2587327 0.463
Platelet ( 103/ml) 232712 237711 0.308
Fasting glucose (mg/dl) 9373 9372 0.689
Plasma renin activity (ng/ml/h) 1.8470.42 2.0570.44 0.435
Plasma aldosterone (ng/dl) 22.172.3 22.372.6 0.393
Urinary IL-1b (ng/g Cr) 81.3725.7 50.077.3 0.653
Urinary TNF-a (ng/g Cr) 104.2725.3 78.6712.8 0.586
Plasma TNF-a (pg/ml) 5.270.8 6.271.0 0.679
Urinary MCP-1 (ng/g Cr) 789.97221.0 423.0778.6 0.009
Plasma MCP-1 (pg/ml) 191.3718.4 184.2716.0 0.381
BP, blood pressure; Cr, creatinine; MCP, monocyte chemoattractant protein; PTX,
pentoxifylline; TNF, tumor necrosis factor.
Before
0
100
200
300
400
500
P = 0.586 P = 0.653 P = 0.009
After Before After Before After
Ur
in
ar
y T
NF
-
 
(ng
/gC
r)
0
100
200
300
400
500
Ur
in
ar
y 
IL
-1
 
(ng
/gC
r)
0
1000
2000
3000
4000
Ur
in
ar
y 
M
CP
-1
 (n
g/g
Cr
)
Figure 2 | Changes of urinary cytokines before and after PTX therapy.
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estimated Cr clearances (Spearman’s coefficient r¼0.395,
P¼ 0.114) or glomerular filtration rates (Spearman’s coeffi-
cient r¼0.345, P¼ 0.167). Moreover, the percent reduction
of urinary protein/Cr ratios after PTX treatment correlated
directly with the precent decrease of urinary MCP-1/Cr ratios
(Spearman’s coefficient r¼ 0.561, P¼ 0.025) (Figure 3).
There was no other parameter that correlated with the
improvement in proteinuria (data not shown).
Although the renal function before and after PTX
treatment remained stable (Table 1), there were two patients
with IgA nephropathy whose glomerular filtration rates
(serum Cr) changed from 24.4 and 23.8 ml/min (2.3 and
2.3 mg/dl) at onset to 20.2 and 18.9 ml/min (2.7 and 2.8 mg/
dl), respectively, 6 months after PTX treatment (Figure 4).
Both patients were hypertensive and received standard
antihypertensive therapies other than angiotensin blockers,
and both displayed stationary or reduced urinary protein
excretion after PTX treatment. By contrast, two patients
whose proteinuria increased after PTX treatment exhibited a
stable renal function during the study.
Six patients discontinued PTX treatment or tapered the
dose of PTX after the end of the study. Among them, four
had a sustained, reduced level of proteinuria during the
ensuing 6 months, whereas two experienced a flare-up of
proteinuria, which was ameliorated by reinstitution of PTX.
The remaining 11 patients chose to continue PTX treatment
for an additional 6 months, and at 1 year the 24-h
proteinuria remained significantly lower than their pre-PTX
levels (3.0170.39 vs 2.0270.29 g/g Cr/day, P¼ 0.0128).
There was no significant change in systolic or diastolic
blood pressure (BP), alanine aminotransferase, potassium,
hemogram, fasting sugar, cholesterol, plasma renin activity or
plasma aldosterone concentrations during the study (Table 1).
No patient discontinued the treatment due to side effects.
One patient experienced gastric upset that disappeared after
taking the drug after meals.
DISCUSSION
This study demonstrates that treatment with PTX in protein-
uric patients with primary glomerular diseases resulted in a
significant reduction of proteinuria, along with an increase of
serum albumin and a decline of urinary MCP-1 levels. These
effects of PTX occurred in the absence of a reduction of
systemic BP. Moreover, a significant correlation was found
between proteinuria and urinary excretion of MCP-1 at basal
of the study, and the reduction of proteinuria following PTX
treatment correlated well with the decrease of urinary
excretion of MCP-1.
This study is limited by lack of a separate control group.
Nevertheless, the beneficial effect of PTX appeared to last
among the 11 patients who continued PTX treatment for 1
year. Further, two out of the six (33%) patients who ceased or
tapered PTX treatment experienced a flare-up of proteinuria,
which could be ameliorated by reinstitution of the drug.
Based on these observations and the results of previous
studies,21–24 we consider PTX an effective agent capable of
reducing proteinuria in our studied patients.
The administration of PTX to our patients did not result
in significant changes of arterial BP or the renin–aldosterone
axis. Thus, the antiproteinuric effect of PTX is not likely
mediated via alterations of hemodynamic processes. Our data
indicate that suppression of renal MCP-1 may be involved in
the decrease of proteinuria. MCP-1 is the strongest known
chemotactic factor for monocytes/macrophages, which plays
an important role in the development of proteinuria due to
glomerular disorders.7–12 Accumulating evidence suggests
that the filtered and subsequently reabsorbed proteins may
activate tubular epithelial cells to release additional MCP-1
into the interstitium, causing further monocyte infiltration
and monocyte activity, and leading ultimately to progressive
interstitial damage seen in many proteinuric glomerular
diseases.28 This assumption is supported by gene therapy
experiments which show that blockade of MCP-1 resulted in
a reduction of proteinuria and/or histological lesions in
murine models of adriamycin nephrosis, lupus nephritis and
unilateral ureteral obstruction nephropathy.29–31 Hence,
urinary MCP-1 is not only a biomarker for glomerular
inflammation13,32 but also a predictor for the progression of
proteinuric glomerular diseases.33 In this study, we show that
the urinary MCP-1 level correlates well with the magnitude of
proteinuria at baseline, and the reduction of urinary MCP-1
Ch
an
ge
s 
in
 u
rin
ar
y 
M
CP
-1
/C
r (
%)
Changes in urinary protein/Cr (%)
−100 −50 0 50 100 150
0
100
200
Figure 3 | The correlation between percent reduction of urinary
protein/Cr ratios and percent reduction of urinary MCP-1/Cr
ratios after PTX therapy.
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Figure 4 | Changes of renal function in the studied patients
before and after PTX therapy. Black circles represent the two
patients with IgA nephropathy exhibiting deterioration of renal
function. GFR denotes glomerular filtration rates.
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levels after PTX treatment correlates strongly with the
decrease of proteinuria. Therefore, the antiproteinuric effect
of PTX might be mediated, at least in part, via down-
regulation of MCP-1 production in the kidney.
Treatment of glomerular diseases consists of general
supportive measures such as BP control and proteinuria
reduction, as well as disease-specific therapies using a
combination of corticosteroids and various immunosuppres-
sive drugs. Due to potentially hazardous side effects, the
immunosuppressive therapy is reserved for patients with
severe glomerular diseases manifest nephrotic syndrome and/
or rapidly deteriorating renal function. In the present study,
most patients manifesting subnephrotic proteinuria at basal
of the study. These patients are usually considered at lower
risk for progressive loss of renal function, and do not need
the relatively toxic immunosuppressive therapy. However, it
is well known that the extent of proteinuria, even at
subnephrotic range, is strongly associated with the outcome
of diabetic nephropathy,16 and the progression of non-
diabetic kidney disease, including primary glomerular
diseases.2,17 Thus, non-immunosuppressive therapies target-
ing mild to moderate proteinuria may still be of benefit for
patients with subnephrotic glomerular diseases. To date,
angiotensin blockade by angiotensin-converting enzyme
inhibitors (ACEi) or type 1 angiotensin II receptor blockers
(ARB), irrespective of BP levels, is the most popular
therapeutic strategy for this subset of patients. These drugs,
however, are not without adverse effects, which include
cough, hyperkalemia and acute downhill of renal function.34
Alternatively, there are other antiproteinuric therapies that
do not act by angiotensin blockade or BP reduction, and are
free of such untoward effects. Among those, the phospho-
diesterase inhibitor PTX has shown its ability to reduce
proteinuria in patients with both diabetic and non-diabetic
nephropathies.21–24 The dose of PTX administered was
generally 1200 mg/day, although in one report 400 mg daily
was used to adjust for the severity of renal failure.23 In the
present study, we demonstrate that PTX, administered at a
relatively lower dose (800 mg daily), can also significantly
decrease proteinuria in patients with proteinuric primary
glomerular diseases, most of them being subnephrotic.
Interestingly, previous studies have shown that PTX is as
effective as ACEi in reducing proteinuria,35 and combination
of PTX with ACEi or ARB results in additive reduction in
microalbuminuria in hypertensive and normotensive type II
diabetics, respectively.36,37 Our previous work has also found
similar additive beneficial effects of PTX in rats with remnant
kidney.25 As the renoprotective effects of ACEi and ARB are
well documented,38 we postulate that treatment with PTX
may have a similar benefit.20
Clinical trials based on anti-MCP-1 strategies have never
been reported in human primary glomerular diseases. The
ACEi, lisinopril, has been shown to attenuate proteinuria and
improve renal function in patients with type II diabetic
nephropathy through suppression of renal MCP-1.39 Of note,
the urinary MCP-1 level in type II diabetic patients was
found to increase in proportion to the degree of proteinuria
and correlate positively with urinary N-acetyl-b-glucosami-
nidase excretion,8 which could be downregulated by PTX.24
As urinary N-acetyl-b-glucosaminidase is a marker of tubular
injury, it is reasonable to speculate that PTX may have
beneficial effects on tubulointerstitial damage in proteinuric
kidney disease. Indeed, our previous studies have shown that
PTX can ameliorate both proteinuria and tubulointerstitial
damage in rats with crescentic glomerulonephritis and
remnant kidney via in part its anti-MCP-1 activity.25,27
Two patients with IgA nephropathy at stage 4 chronic
kidney disease in this study exhibited deteriorating renal
function despite an optimal control of urinary MCP-1,
proteinuria and arterial BP. As pre-existing renal insufficiency
is a strong predictor of poor prognosis for IgA nephro-
pathy,40 monotherapy with PTX may not be sufficient to
retard renal progression in such high-risk patients. Further,
previous pharmacokinetic studies of PTX indicate that
800 mg daily is a maximum for patients with moderate renal
dysfunction,41 escalation of dose may not be an option for
these patients. We surmise that a multi-drug approach
combining PTX and angiotensin blockers such as ACEi or
ARB may be needed to provide greater renoprotection. Due
to the small sample size and the limited follow-up period of
this study, further randomized clinical trials are required
to verify the renoprotective potential of PTX in patients
with primary glomerular diseases, in particular those
with renal insufficiency at presentation. It is noteworthy
that two patients whose proteinuria increased during the
study exhibited a rather stable renal function. Although
the limited period of follow-up may have contributed to
such a paradox, our observation underscores the need for
new surrogate markers besides proteinuria in predicting the
renal outcome.42,43
Somewhat to our surprise, this study fails to confirm
previous findings that PTX can reduce plasma or urinary
TNF-a in proteinuric glomerular disorders.21,23,37 The
reasons for this divergent result are not clear, but may be
due to differences in PTX dose, variations in proteinuria
magnitude or heterogeneity in glomerular pathologies among
the studied subjects. In this study, the reduction of
proteinuria after PTX treatment correlated best with the
decrease of urinary MCP-1, thereby suggesting a preferential
role of the urinary MCP-1 level in predicting therapeutic
efficacy of PTX. This is reminiscent of the works which show
that the elevated urinary MCP-1, but not other classes of
chemokines such as IL-8 or fractalkine, is a more sensitive
biomarker for disease activity in renal lupus and antineutro-
phil cytoplasmic antibody-associated vasculitis,13,32 although
urinary TNF-a or IL-1b levels were not measured in those
studies.
In conclusion, this study shows that administration of
PTX 800 mg/day is both safe and effective for reducing
proteinuria in patients with proteinuric primary glomerular
diseases, and this beneficial effect may be mediated through
suppression of renal MCP-1 production by this drug.
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MATERIALS AND METHODS
The study was approved by the human research ethics committee of
the National Taiwan University Hospital (No. 152S2). Adult patients
affected by primary glomerular diseases with proteinuria were
screened for the study. Patients were eligible for enrollment if
urinary protein/Cr ratios exceeded 1.5 g/g Cr in 3 consecutive single-
voided urine samples, and renal function was stable for at least 3
months. To minimize selection bias, we consecutively enrolled
patients. Patients were excluded from the study if they had abnormal
liver function, diabetes mellitus, hereditary kidney diseases or
immunologic renal diseases such as Henoch–Schonlein purpura,
systemic lupus erythematosus or antineutrophil cytoplasmic anti-
body-associated vasculitis. Seventeen patients (four males, 13
females, aged 35–85 years) with a persistent spot proteinuria of
1.51–5.67 g/g Cr, and a serum Cr between 0.6 and 2.3 mg/dl (Cr
clearances ranging from 27 to 105 ml/min, glomerular filtration
rates ranging from 24 to 115 ml/min/1.73 m2) were finally selected.
All the eligible patients gave their consent to the study, including
two nephrotic patients who refused corticosteroid therapy. Twelve
patients were diagnosed as glomerulonephritis by renal biopsy,
including focal segmental glomerulosclerosis in one case, mesangial
proliferative glomerulonephritis in one case, IgA nephropathy in five
cases and membranous nephropathy in five cases. The remaining
five patients were diagnosed as glomerular diseases by demonstrat-
ing predominantly albuminuria (X70%) on urine protein electro-
phoresis with or without dysmorphic red blood cells on urinalysis.
PTX 400 mg was administered orally twice a day for 6 months.
Patients did not receive corticosteroids, statins, ACEi, ARB or
antiplatelet agents such as dipyridamole or aspirin throughout the
study period. Diuretics, calcium channel antagonists or adrenocep-
tor blockers were administered to optimize BP control whenever
needed.
Before and 6 months after the treatment, blood and single-
voided urine samples were collected in endotoxin-free tubes. Plasma
and urinary TNF-a, IL-1b and MCP-1 concentrations were
measured in duplicate using commercially available enzyme-linked
immunosorbent assay kits specific for TNF-a, IL-1b, and MCP-1
(Endogen, Woburn, MA, USA). Plasma renin activity and plasma
aldosterone concentrations were measured in duplicate using
commercially available radioimmunoassay kits (Rianen, DuPont,
Boston, MA, USA; Aldosterone Maia, Biodata Diagnostics, Rome,
Italy). Cr levels were measured using a standard colorimetric
method (Jaffe rate reaction), and urine protein concentrations were
quantitated by Biorad’s method. The magnitude of urinary protein
excretion was represented by urinary protein/Cr ratio in both single-
voided44 and 24-h urine samples. The Cr clearance was estimated by
the Cockcroft–Gault equation45 and the glomerular filtration rate
determined by the simplified Modification of Diet in Renal Disease
formula.46 All biochemical analyses were performed by the
Department of Laboratory Medicine, National Taiwan University
Hospital. Clinic arterial BP was measured in a sitting position using
a standard mercury sphymomanometer.
Student’s t-test and Wilcoxon rank sign test were performed to
evaluate the differences in continuous and non-normally distributed
variables before and 6 months after PTX treatment when
appropriate. Spearman’s rank correlation test was performed to
determine the variables that significantly affected urinary protein
excretion. Data are expressed as mean7s.e.m. Any probability
values o0.05 were considered significant. Stat-View package
(version 4.52) for the Macintoch computer was used for statistical
analysis (Abacus Concepts, Berkeley, CA, USA).
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